Workflow
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

Core Insights - Maravai LifeSciences has published its 2024 Sustainability Report, highlighting progress in product innovation, employee engagement, governance, and sustainable growth [2][3] Product Innovation - Launched 49 new products, including the CleanCap® M6 analog at GMP quality [6] - Completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold [6] - Established an RNA Innovation Center in collaboration with Johns Hopkins University [6] - Manufactured over 130 GMP batches for mRNA [6] Our People - Achieved a 95% participation rate in the annual employee engagement survey, receiving over 2,600 comments [6] - Expanded the WE (We are Empowered) Employee Resource Group for advocacy, mentorship, and outreach [6] - Implemented a new career framework for transparent progression paths for all employees [6] - Continued the Impact Day program, with employees contributing approximately 800 volunteer hours [6] Governance - Appointed R. Andrew Eckert as independent Chairman of the Board [6] - Adopted a formal, publicly available Human Rights Policy [6] - Ensured 100% of standing Board Committees are chaired by independent members [6] - Strengthened intellectual property with additional CleanCap® patents in China and Canada [6] Sustainable Growth - Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting [11] - The Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of the facility's energy use [11] - San Diego EV charging stations saved over 19,000 gallons of gasoline [11] - Advanced planning for lab plastics recycling and single-use plastic phase-out [11] Reporting Standards - The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and Greenhouse Gas Protocol frameworks [8]